LGALS3BP (F2K6Q) Rabbit mAb #38514

LGALS3BP is a complex, hyperglycosylated, secreted protein that is involved in regulating a number of important biological processes. These include cell signaling and adhesion, migration, proliferation, and potentially immune response regulation via natural killer cell function (1,2,3). Upon secretion of LGALS3BP into the extracellular matrix (ECM), it interacts with galectins, such as LGALS-3, and ECM components, such as fibrinogen and collagen, as well as members of the integrin family (4). LGALS3BP binding to LGALS-3 modulates LGALS-3 activity and results in downstream changes in cell-cell and cell-matrix interactions (1).

Essentially, LGALS3BP-mediated integrin activation triggers intracellular signaling pathways, including the Akt, JNK, and Ras-ERK cascades. These pathways are essential for cell proliferation and survival. Essentially, LGALS3BP can activate signaling pathways that promote cell growth. Not surprisingly, therefore, LGALS3BP is overexpressed in certain pathological conditions, notably in various cancers, including pancreatic, lung, and breast cancers, hepatocellular carcinoma, and other tumor types. (3-6).  Overexpression is associated with tumor progression, metastasis, and poor prognosis (5). It plays a role in other disease conditions, such as hepatic fibrosis, where it influences TGF-β1 signaling and availability, viral infections, such as HIV, and autoimmune diseases, such as systemic lupus erythematosus (2-7).

LGALS3BP is a multifaceted protein with significant roles in cell biology and disease. Its involvement in cancer progression and other pathological conditions makes it an area of active research, and overexpression in tumors makes it a promising target for diagnostic antibodies and drug development (4,8,9).